H

Hinova Pharmaceuticals Inc
SSE:688302

Watchlist Manager
Hinova Pharmaceuticals Inc
SSE:688302
Watchlist
Price: 47.23 CNY -1.91% Market Closed
Market Cap: ¥4.7B

Operating Margin

-1 337.2%
Current
Improving
by 76 548.1%
vs 3-y average of -77 885.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 337.2%
=
Operating Income
¥-179.5m
/
Revenue
¥13.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 337.2%
=
Operating Income
¥-179.5m
/
Revenue
¥13.4m

Peer Comparison

Country Company Market Cap Operating
Margin
CN
Hinova Pharmaceuticals Inc
SSE:688302
4.7B CNY
Loading...
US
Eli Lilly and Co
NYSE:LLY
969.6B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.3B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Lower than 99% of companies in China
Percentile
1st
Based on 8 544 companies
1st percentile
-1 337.2%
Low
-409 046.1% — -1.4%
Typical Range
-1.4% — 10.3%
High
10.3% — 876.4%
Distribution Statistics
China
Min -409 046.1%
30th Percentile -1.4%
Median 4.2%
70th Percentile 10.3%
Max 876.4%

Hinova Pharmaceuticals Inc
Glance View

Market Cap
4.7B CNY
Industry
Pharmaceuticals

Hinova Pharmaceuticals, Inc. engages in the research and development of pharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 160 full-time employees. The company went IPO on 2022-04-12. The firm focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The firm's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The firm has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The firm conducts clinical tests in domestic and overseas areas.

Intrinsic Value
2.77 CNY
Overvaluation 94%
Intrinsic Value
Price
H
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 337.2%
=
Operating Income
¥-179.5m
/
Revenue
¥13.4m
What is Hinova Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Hinova Pharmaceuticals Inc is -1 337.2%, which is above its 3-year median of -77 885.3%.

How has Operating Margin changed over time?

Over the last 3 years, Hinova Pharmaceuticals Inc’s Operating Margin has increased from -20 467% to -1 337.2%. During this period, it reached a low of -235 121.3% on Jun 30, 2024 and a high of -1 337.2% on Jul 30, 2025.

Back to Top